Jan N De Hoon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4892808/publications.pdf

Version: 2024-02-01

93 papers 3,463 citations

33 h-index 55 g-index

94 all docs 94 docs citations 94 times ranked 4038 citing authors

#	Article	IF	CITATIONS
1	Novel antibody cocktail targeting Bet $v\ 1$ rapidly and sustainably treats birch allergy symptoms in a phase 1 study. Journal of Allergy and Clinical Immunology, 2022, 149, 189-199.	2.9	38
2	The PET tracer [¹¹ C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's disease. Science Translational Medicine, 2022, 14, eabg3684.	12.4	10
3	Low-dose capsaicin (0.01 mM) nasal spray is equally effective as the current standard treatment for idiopathic rhinitis: AArandomized, double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2021, 147, 397-400.e4.	2.9	7
4	Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 596-611.	6.4	16
5	TRP Channel Cooperation for Nociception: Therapeutic Opportunities. Annual Review of Pharmacology and Toxicology, 2021, 61, 655-677.	9.4	54
6	Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density. EJNMMI Physics, 2021, 8, 37.	2.7	3
7	Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function. Scientific Reports, 2021, 11, 16172.	3.3	6
8	Doppler Ultrasound to assess the pharmacodynamic effects of splanchnic vasoactive compounds. British Journal of Clinical Pharmacology, 2021, , .	2.4	0
9	Laser speckle contrast imaging, the future DBF imaging technique for TRP target engagement biomarker assays. Microvascular Research, 2020, 129, 103965.	2.5	7
10	Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial. Vaccine, 2020, 38, 3227-3234.	3.8	7
11	Pharmacokinetics during therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy: a literature review. BMJ Paediatrics Open, 2020, 4, e000685.	1.4	26
12	In vivo <scp>CYP</scp> 3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 50-55.	2.5	4
13	Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	13
14	¹⁸ F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. Journal of Nuclear Medicine, 2019, 60, 683-690.	5.0	63
15	Phase I, Randomized, Doubleâ€blind, Placeboâ€controlled, Singleâ€dose, and Multipleâ€dose Studies of Erenumab in Healthy Subjects and Patients With Migraine. Clinical Pharmacology and Therapeutics, 2018, 103, 815-825.	4.7	71
16	Antenatal sildenafil administration to prevent pulmonary hypertension in congenital diaphragmatic hernia (SToP-PH): study protocol for a phase I/IIb placenta transfer and safety study. Trials, 2018, 19, 524.	1.6	27
17	Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers. Drug Metabolism and Disposition, 2018, 46, 1507-1513.	3.3	17
18	RVCL-S and CADASIL display distinct impaired vascular function. Neurology, 2018, 91, e956-e963.	1.1	23

#	Article	IF	Citations
19	Determinants of tramadol metabolism in neonates and young infants differ when based on either plasma or urine samples. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-15-8.	0.0	0
20	Body weight, gender and pregnancy affect enantiomerâ€specific ketorolac pharmacokinetics. British Journal of Clinical Pharmacology, 2017, 83, 1966-1975.	2.4	8
21	Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. Pharmaceutical Research, 2017, 34, 1784-1795.	3.5	75
22	Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. BioDrugs, 2017, 31, 447-459.	4.6	65
23	What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2. Journal of Nuclear Medicine, 2017, 58, 110-116.	5.0	31
24	Development of an <i>in vivo</i> targetâ€engagement biomarker for TRPA1 antagonists in humans. British Journal of Clinical Pharmacology, 2017, 83, 603-611.	2.4	12
25	The influence of migraine and female hormones on capsaicin-induced dermal blood flow. Cephalalgia, 2017, 37, 1164-1172.	3.9	34
26	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers. Frontiers in Pharmacology, 2017, 8, 740.	3.5	54
27	Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period. Bosnian Journal of Basic Medical Sciences, 2017, 17, 54-60.	1.0	8
28	EUFEMED London Conference 2017: Exploratory Medicines Development: Innovation and Risk Management. Frontiers in Pharmacology, 2017, 8, 901.	3.5	2
29	GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817) Journal of Clinical Oncology, 2017, 35, TPS2605-TPS2605.	1.6	5
30	SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants. Therapeutic Drug Monitoring, 2016, 38, 487-492.	2.0	20
31	Drug disposition before and after gastric bypass: fenofibrate and posaconazole. British Journal of Clinical Pharmacology, 2016, 82, 1325-1332.	2.4	24
32	Paracetamol pharmacokinetics and metabolism in young women. BMC Anesthesiology, 2015, 15, 163.	1.8	16
33	Development of antiâ€migraine therapeutics using the capsaicinâ€induced dermal blood flow model. British Journal of Clinical Pharmacology, 2015, 80, 992-1000.	2.4	29
34	Characterization of the novel GlyT1 PET tracer [¹⁸ F]MKâ€6577 in humans. Synapse, 2015, 69, 33-40.	1.2	17
35	Tramadol and O-Desmethyl Tramadol Clearance Maturation and Disposition in Humans: A Pooled Pharmacokinetic Study. Clinical Pharmacokinetics, 2015, 54, 167-178.	3.5	45
36	Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants. European Journal of Clinical Pharmacology, 2015, 71, 1075-1082.	1.9	30

#	Article	IF	Citations
37	Characterizing the <scp>PK</scp> / <scp>PD</scp> relationship for inhibition of capsaicinâ€induced dermal vasodilatation by <scp>MK</scp> â€3207, an oral calcitonin gene related peptide receptor antagonist. British Journal of Clinical Pharmacology, 2015, 79, 831-837.	2.4	20
38	Drug disposition and modelling before and after gastric bypass: immediate and controlledâ€release metoprolol formulations. British Journal of Clinical Pharmacology, 2015, 80, 1021-1030.	2.4	25
39	Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 350-357.	2.5	48
40	Quantification, Variability, and Reproducibility of Basal Skeletal Muscle Glucose Uptake in Healthy Humans Using ¹⁸ F-FDG PET/CT. Journal of Nuclear Medicine, 2015, 56, 1520-1526.	5.0	14
41	Low but Inducible Contribution of Renal Elimination to Clearance of Propylene Glycol in Preterm and Term Neonates. Therapeutic Drug Monitoring, 2014, 36, 278-287.	2.0	16
42	11C-MK-8278 PET as a Tool for Pharmacodynamic Brain Occupancy of Histamine 3 Receptor Inverse Agonists. Journal of Nuclear Medicine, 2014, 55, 65-72.	5.0	23
43	Determination of Racemic Ketorolac, Ketorolac Enantiomers and Their Metabolites in Human Plasma and Urine by LC–UV, Applied in Clinical Study During and After Pregnancy. Chromatographia, 2014, 77, 803-812.	1.3	3
44	Urinary metabolites after intravenous propofol bolus in neonates. European Journal of Drug Metabolism and Pharmacokinetics, 2013, 38, 97-103.	1.6	5
45	The impact of pregnancy on urinary ketorolac metabolites after single intravenous bolus. European Journal of Drug Metabolism and Pharmacokinetics, 2013, 38, 1-4.	1.6	4
46	Pharmacokinetics of paracetamol and its metabolites in women at delivery and postâ€partum. British Journal of Clinical Pharmacology, 2013, 75, 850-860.	2.4	47
47	Evaluation of [18F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human. NeuroImage, 2013, 68, 1-10.	4.2	24
48	Developmental pharmacokinetics of propylene glycol in preterm and term neonates. British Journal of Clinical Pharmacology, 2013, 75, 162-171.	2.4	35
49	In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [¹¹ C]MK-4232. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 478-486.	2.5	114
50	Effective analgesia after cesarean delivery needs pharmacokinetic input. Journal of Anaesthesiology Clinical Pharmacology, 2012, 28, 409.	0.7	2
51	A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel. Platelets, 2012, 23, 249-258.	2.3	17
52	The Impact of Caesarean Delivery on Paracetamol and Ketorolac Pharmacokinetics: A Paired Analysis. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-5.	3.0	9
53	The pharmacokinetics of a high intravenous dose of paracetamol after caesarean delivery. European Journal of Anaesthesiology, 2012, 29, 484-488.	1.7	7
54	Tu1469 Evaluation of a New Motilin Receptor Agonist, GSK962040, on the Migrating Motor Complex and Gastric pH in Healthy Human Volunteers. Gastroenterology, 2012, 142, S-841.	1.3	1

#	Article	IF	Citations
55	The propylene glycol research project to illustrate the feasibility and difficulties to study toxicokinetics in neonates. International Journal of Pharmaceutics, 2012, 435, 112-114.	5.2	21
56	Biochemical tolerance during low dose propylene glycol exposure in neonates: A formulation-controlled evaluation. DARU, Journal of Pharmaceutical Sciences, 2012, 20, 5.	2.0	9
57	Interictal Type 1 Cannabinoid Receptor Binding is Increased in Female Migraine Patients. Headache, 2012, 52, 433-440.	3.9	25
58	The effects of laropiprant, a selective prostaglandin D2receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets, 2011, 22, 495-503.	2.3	9
59	The potent calcitonin geneâ€related peptide receptor antagonist, telcagepant, does not affect nitroglycerinâ€nduced vasodilation in healthy men. British Journal of Clinical Pharmacology, 2011, 71, 708-717.	2.4	31
60	Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects., 2011, 129, 332-351.		58
61	Determination of Propylene Glycol in Low Volume Plasma and Urine Samples of Neonates by LC with Photodiode Array Detection. Chromatographia, 2011, 73, 463-470.	1.3	10
62	Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis. European Journal of Clinical Pharmacology, 2011, 67, 753-755.	1.9	22
63	Does intravenous paracetamol administration affect body temperature in neonates?. Archives of Disease in Childhood, 2011, 96, 301-304.	1.9	18
64	Substantial Variation in Transplacental Transfer of Chemotherapeutic Agents in a Mouse Model. Reproductive Sciences, 2011, 18, 57-63.	2.5	48
65	Comments on â€~Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers'. Cephalalgia, 2011, 31, 380-380.	3.9	2
66	Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 1338-1345.	2.8	101
67	Dose-dependent effects of the CRF1 receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology, 2010, 208, 109-119.	3.1	30
68	Endothelial function in migraine: a cross-sectional study. BMC Neurology, 2010, 10, 119.	1.8	26
69	Increasing the dose of voriconazole compensates for enzyme induction by phenytoin. British Journal of Clinical Pharmacology, 2010, 69, 701-702.	2.4	5
70	Renal Side Effects of Non-Steroidal Anti-Inflammatory Drugs in Neonates. Pharmaceuticals, 2010, 3, 393-405.	3.8	8
71	Prospective assessment of short-term propylene glycol tolerance in neonates. Archives of Disease in Childhood, 2010, 95, 1054-1058.	1.9	49
72	The use of diameter distension waveforms as an alternative for tonometric pressure to assess carotid blood pressure. Physiological Measurement, 2010, 31, 543-553.	2.1	43

#	Article	IF	Citations
73	No arguments for increased endothelial nitric oxide synthase activity in migraine based on peripheral biomarkers. Cephalalgia, 2010, 30, 1354-1365.	3.9	5
74	Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. International Journal of Gynecological Cancer, 2010, 20, 1456-64.	2.5	75
75	The interindividual variability in metabolism of the analgesic tramadol in neonates is independent of their disease state characteristics. Journal of Neonatal-Perinatal Medicine, 2009, 2, 115-122.	0.8	0
76	Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Medicine, 2009, 35, 603-612.	8.2	62
77	Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. American Journal of Obstetrics and Gynecology, 2009, 200, 170.e1-170.e7.	1.3	37
78	Relationship of Type 1 Cannabinoid Receptor Availability in the Human Brain to Novelty-Seeking Temperament. Archives of General Psychiatry, 2009, 66, 196.	12.3	61
79	In Vivo Characterization and Dynamic Receptor Occupancy Imaging of TPA023B, an α2∫α3∫α5 Subtype Selective γ-Aminobutyric Acid–A Partial Agonist. Biological Psychiatry, 2008, 64, 153-161.	1.3	23
80	The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake. Cell Metabolism, 2008, 7, 68-78.	16.2	198
81	Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [18F]MK-9470 PET. NeuroImage, 2008, 39, 1533-1541.	4.2	117
82	Postmenstrual Age and CYP2D6 Polymorphisms Determine Tramadol O-demethylation in Critically Ill Neonates and Infants. Pediatric Research, 2008, 63, 674-679.	2.3	56
83	Multipleâ€Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoidâ€1 Receptor Inverse Agonist, in Healthy Male Volunteers. Journal of Clinical Pharmacology, 2008, 48, 734-744.	2.0	47
84	[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9800-9805.	7.1	300
85	Altered arterial function in migraine of recent onset. Neurology, 2007, 68, 1563-1570.	1.1	182
86	Determinants of Drug Metabolism in Early Neonatal Life. Current Clinical Pharmacology, 2007, 2, 23-29.	0.6	39
87	Maturational pharmacokinetics of single intravenous bolus of propofol. Paediatric Anaesthesia, 2007, 17, 1028-1034.	1.1	98
88	Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. European Journal of Pharmaceutical Sciences, 2005, 24, 179-186.	4.0	140
89	The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age. Pediatric Nephrology, 2005, 20, 740-743.	1.7	36
90	Nonselective cyclo-oxygenase inhibitors and glomerular filtration rate in preterm neonates. Pediatric Nephrology, 2005, 20, 1557-1561.	1.7	39

#	Article	IF	CITATIONS
91	Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. European Journal of Clinical Pharmacology, 2004, 60, 191-197.	1.9	100
92	Calcitonin gene?related peptide: exploring its vasodilating mechanism of action in humans. Clinical Pharmacology and Therapeutics, 2003, 73, 312-321.	4.7	50
93	<scp>Firstâ€inâ€human</scp> development of a pharmacodynamic biomarker for <scp> PAC ₁ </scp> receptor antagonists using intradermal injections of maxadilan. Clinical and Translational Science, 0, , .	3.1	2